Hundreds of jobs to be created as part of US-owned Sligo plastics firm expansion
MedTech group Iqvia is also set to create 100 jobs in Dublin
Hundreds of jobs are to be created in Sligo as part of the international expansion of a US-headquartered plastics manufacturer.
Vermont-based GW Plastics, which bought Avenue Mould Solutions two years ago, is expanding its workforce here by more than 200.
The company plans to expand its moulding operations into a scalable 23,000 sq ft site in Sligo town.
Roles in the areas of production, quality, regulatory, and engineering will be made available.
Established in the 1980s, Avenue's acquisition by GW Plastics is part of the US firm's continuing global growth.
GW Plastics, which manufactures injection moulding for the medtech and pharma industries, employs more than 1,200 people worldwide.
In addition to the Irish hub at Finisklin Industrial Estate, the company has plants in the US, Mexico and China.
Taoiseach, Leo Varadkar TD said that Sligo is recognised as a major regional centre and a driver of economic development and that the Government is investing in the North West region through major infrastructure projects like the new N4.
"We want to help each region build on its unique strengths and ensure they are leveraged for enterprise development," he said.
GW Plastics said it plans to invest €5.7m to grow their product development, thermoplastic and silicone injection moulding, and contract assembly capabilities in Europe.
Separately, MedTech group Iqvia, a global technology solutions and contract research services provider, announced that it is set to create 100 jobs in Dublin.
The new roles are in the areas of clinical project management, data management, drug safety and biostatistics.
In particular, Iqvia is recruiting pharmacovigilance - or drug safety - specialists, across a variety of safety services spanning both clinical trials and medicines. There will also be a number of opportunities available for life science graduates.
Recruitment is already underway for the positions, which will be based at the group’s East Point campus in Dublin.
Martin Giblin, country head of Iqvia Ireland, said: "Ireland is a strategically important location for Iqvia, and today’s announcement represents a significant step in increasing our capability to serve our pharma customers across Europe and the world."
"Ireland has a rich base of life sciences talent, is a great place to do business and we look forward to continuing to grow our business here."
The news was welcomed by both the Minister for Finance, Paschal Donohoe TD, and IDA Ireland.
"Ireland’s ability to retain companies such as Iqvia is a testament to our attractive business environment, robust regulatory framework, and skilled labour force," Minister Donohoe said.
"We are delighted to see an industry leader that supports the pharma and life science sector continuing its expansion, which will enable Iqvia to serve more customers with their innovative technology around the world," he added.